StockLumo

DYADIC INTERNATIONAL INC (DYAI): Form 8-K filed 2026-11-13

Accepted by EDGAR
2026-11-13 11:57 ET
Event date
2026-11-12
Accession no.
0001493152-26-051601
Original filing
SEC EDGAR filing index

AI summary of the filing text. It can contain mistakes; the original filing is authoritative.

Dyadic reports third quarter 2026 results and first direct commercial product sales

Dyadic reported revenue of $449,101 and a net loss of $1,357,041 for the three months ended September 30, 2026. It recorded its first direct commercial product sales, primarily recombinant transferrin and DNase I, though initial sales were not material. Management concluded there is substantial doubt about its ability to continue as a going concern for the 12 months following November 12, 2026.

earningsproduct

Items reported

Documents

TypeDescriptionDocument
8-K8-Kform8-k.htm
EX-99.1EX-99.1ex99-1.htm

The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.